• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Novartis ’ Spinal Drug Gets FDA Approval, $2 Million Price Tag
(CNN) — The US Food and Drug Administration approved a treatment Friday for a genetic disease called spinal muscular atrophy that causes infants’ muscles to waste away, potentially killing them before age 2. And then came the price tag: $2.125 million for a one-time treatment. The gene therapy, called Zolgensma, will be marketed by AveXis, whose parent company is Novartis. “Today’s approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” Dr. Ned Sharpless, the FDA’s acting commissioner, said in a statement Friday. ̶...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Novartis Source Type: news

10 Global Health Issues to Watch in 2018
January 19, 2018It ’s notallbad news.When we set out to compile our annual list of global health issues to watch this year, it seemed like all bad news. And true, that ’s often what we deal with in global health—the problems that need tackling, the suffering we can help alleviate.But then stories and columns likethis one cheer us up. They remind us that no matter how complicated and frustrating our work may get, fighting back against poverty and inequality works.There are and always will be global health challenges to face. But there ’s boundless hope, too. And a field full of determined health workers and other hu...
Source: IntraHealth International - January 19, 2018 Category: International Medicine & Public Health Authors: mnathe Source Type: news